- Home
- PPBT vs BMRA Comparison
PPBT vs BMRA Comparison
Compare PPBT & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- BMRA
- Stock Information
- Founded
- PPBT 2010
- BMRA 1971
- Country
- PPBT Israel
- BMRA United States
- Employees
- PPBT N/A
- BMRA N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PPBT Health Care
- BMRA Health Care
- Exchange
- PPBT Nasdaq
- BMRA Nasdaq
- Market Cap
- PPBT 7.4M
- BMRA 8.2M
- IPO Year
- PPBT N/A
- BMRA N/A
- Fundamental
- Price
- PPBT $0.71
- BMRA $2.45
- Analyst Decision
- PPBT Strong Buy
- BMRA
- Analyst Count
- PPBT 1
- BMRA 0
- Target Price
- PPBT $33.00
- BMRA N/A
- AVG Volume (30 Days)
- PPBT 21.8M
- BMRA 30.0K
- Earning Date
- PPBT 11-14-2025
- BMRA 10-14-2025
- Dividend Yield
- PPBT N/A
- BMRA N/A
- EPS Growth
- PPBT N/A
- BMRA N/A
- EPS
- PPBT N/A
- BMRA N/A
- Revenue
- PPBT N/A
- BMRA $4,884,000.00
- Revenue This Year
- PPBT N/A
- BMRA N/A
- Revenue Next Year
- PPBT N/A
- BMRA N/A
- P/E Ratio
- PPBT N/A
- BMRA N/A
- Revenue Growth
- PPBT N/A
- BMRA N/A
- 52 Week Low
- PPBT $0.53
- BMRA $2.08
- 52 Week High
- PPBT $13.95
- BMRA $10.16
- Technical
- Relative Strength Index (RSI)
- PPBT 45.98
- BMRA 33.88
- Support Level
- PPBT $0.71
- BMRA $2.36
- Resistance Level
- PPBT $0.89
- BMRA $2.56
- Average True Range (ATR)
- PPBT 0.13
- BMRA 0.12
- MACD
- PPBT 0.01
- BMRA -0.02
- Stochastic Oscillator
- PPBT 17.37
- BMRA 13.64
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.